C

Celon Pharma SA
WSE:CLN

Watchlist Manager
Celon Pharma SA
WSE:CLN
Watchlist
Price: 27 PLN -0.18%
Market Cap: 1.5B PLN
Have any thoughts about
Celon Pharma SA?
Write Note

Celon Pharma SA
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Celon Pharma SA
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
C
Celon Pharma SA
WSE:CLN
Accounts Receivables
zł48.5m
CAGR 3-Years
10%
CAGR 5-Years
7%
CAGR 10-Years
N/A
M
Molecure SA
WSE:MOC
Accounts Receivables
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Cannabis Poland SA
WSE:CBD
Accounts Receivables
zł36.3k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Celon Pharma SA
Glance View

Market Cap
1.4B PLN
Industry
Pharmaceuticals

Celon Pharma SA is a pharmaceutical company, which engages in the research and manufacture of modern drugs. The firm focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The firm's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The firm is a subsidiary of Glatton sp z o o.

CLN Intrinsic Value
9.2 PLN
Overvaluation 66%
Intrinsic Value
Price
C

See Also

What is Celon Pharma SA's Accounts Receivables?
Accounts Receivables
48.5m PLN

Based on the financial report for Jun 30, 2024, Celon Pharma SA's Accounts Receivables amounts to 48.5m PLN.

What is Celon Pharma SA's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
7%

Over the last year, the Accounts Receivables growth was 52%. The average annual Accounts Receivables growth rates for Celon Pharma SA have been 10% over the past three years , 7% over the past five years .

Back to Top